HP2 Laboratory, Inserm Unit 1042, University Grenoble Alpes, Grenoble, France; EFCR Laboratory, Pole Thorax et Vaisseaux, Grenoble Alpes University Hospital, Grenoble, France; Pharmacovigilance Department, Grenoble Alpes University Hospital, Grenoble, France.
HP2 Laboratory, Inserm Unit 1042, University Grenoble Alpes, Grenoble, France; EFCR Laboratory, Pole Thorax et Vaisseaux, Grenoble Alpes University Hospital, Grenoble, France.
Chest. 2020 Jul;158(1):359-364. doi: 10.1016/j.chest.2020.01.050. Epub 2020 Feb 29.
Diuretics have been reported as effective for reducing OSA severity by preventing fluid retention and reducing rostral fluid shift. The benefit of diuretics might vary depending on the OSA clinical phenotype and comorbidities. To test this hypothesis, we conducted a propensity score-matched cohort analysis of data from the French national sleep apnea registry "Observatoire Sommeil de la Fédération de Pneumologie."
Which phenotypic subtypes of OSA may benefit from diuretics?
A propensity score analysis was used to determine the impact of diuretics on OSA severity. Matching (ratio 1:4) was performed by using a 0.1 collider for the propensity score. Severe OSA was defined as an apnea-hypopnea index (AHI) > 30 events/h, and the usefulness of diuretics was assessed by using a logistic regression model.
The 69,564 OSA patients studied in the OSFP prospective observational cohort had a median age of 56.9 years (interquartile range: 47.4; 65.6), 67% were men, and the median AHI was 28 (14; 43) events/h. Among them, 9,783 (14.1%) were treated with diuretics. Diuretics reduced OSA severity in overweight or moderately obese patients (P = .03) and in patients with hypertension (P < .01), particularly in patients with hypertension with a BMI between 25 and 35 (P < .01). Diuretics had no significant effect on OSA severity in patients with self-reported low physical activity or heart failure.
Diuretics appear to have a positive impact on OSA severity in overweight or moderately obese patients with hypertension. A prospective study is needed to confirm that diuretics are of interest in combined therapies for hypertensive patients with OSA.
利尿剂通过防止液体潴留和减少颅液移位已被报道可有效降低 OSA 严重程度。利尿剂的益处可能因 OSA 临床表型和合并症而异。为了检验这一假设,我们对来自法国国家睡眠呼吸暂停登记处“Observatoire Sommeil de la Fédération de Pneumologie”的数据进行了倾向评分匹配队列分析。
哪种 OSA 表型亚型可能受益于利尿剂?
使用倾向评分分析来确定利尿剂对 OSA 严重程度的影响。通过使用倾向评分的 0.1 碰撞器进行匹配(比例为 1:4)。重度 OSA 定义为呼吸暂停低通气指数(AHI)>30 次/小时,使用逻辑回归模型评估利尿剂的有用性。
在 OSFP 前瞻性观察队列中研究的 69564 例 OSA 患者的中位年龄为 56.9 岁(四分位间距:47.4;65.6),67%为男性,中位 AHI 为 28(14;43)次/小时。其中,9783 例(14.1%)接受了利尿剂治疗。利尿剂可降低超重或中度肥胖患者(P=0.03)和高血压患者(P<0.01)的 OSA 严重程度,尤其是 BMI 在 25 至 35 之间的高血压患者(P<0.01)。利尿剂对自我报告体力活动低或心力衰竭的 OSA 严重程度无显著影响。
利尿剂似乎对超重或中度肥胖合并高血压的 OSA 患者的严重程度有积极影响。需要进行前瞻性研究以确认利尿剂对合并高血压和 OSA 的患者的联合治疗是否有意义。